[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.92.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1993

Adoption of a New Haemophilus influenzae Type b Vaccine Recommendation

Author Affiliations

The Robert Wood Johnson Clinical Scholars Program The Cecil G. Sheps Center for Health Services Research Division of Community Pediatrics University of North Carolina at Chapel Hill CB 7490 Chase Hall Chapel Hill, NC 27599-7490
The Cecil G. Sheps Center for Health Services Research
Division of Community Pediatrics University of North Carolina at Chapel Hill

Am J Dis Child. 1993;147(2):124-128. doi:10.1001/archpedi.1993.02160260014004
Abstract

Sir.—Haemophilus influenzae type b (Hib) infection in children is responsible for approximately 12 000 cases of meningitis and 7500 cases of other invasive diseases annually in the United States,1,2 with a mortality rate of 5% in cases of meningitis and as many as 40% of survivors having significant neurologic sequelae.3

On October 4, 1990, the Food and Drug Administration (FDA) permitted one Hib vaccine manufacturer to amend its package insert to claim safety and efficacy for administration at age 2 months.4 The previous recommended age of first administration had been 15 months. The American Academy of Pediatrics (AAP) soon issued a recommendation for first administration to infants at age 2 months.

A letter called a Ped-Comm was sent from the AAP to its members in late October 1990 recommending the earlier age for first vaccination, but information on safety or efficacy was not included since

First Page Preview View Large
First page PDF preview
First page PDF preview
×